AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Alexion, AstraZeneca Rare Disease (alexion.com)
Alexion manages to avoid high BS scores primarily through the ‘boring substance’ of regulatory compliance and clear citations. While the top-level copy is thick with pharma-fluff, the secondary layers provide the names, dates, and references required for industry credibility.
Populate the ‘Innovation’ sub-page with specific Phase I-III pipeline data to replace the current generic AI and Genomics blocks. Integrate Person schema for all named ‘Leading Voices’ to provide a verifiable digital footprint for their expertise. Replace the H1 power-word ‘Pioneering’ with a more specific verb that references a recent regulatory milestone or therapeutic area expansion. Add direct links to ClinicalTrials.gov for the ‘Patient-Centric Trial Design’ section to bridge the proof gap.
The site exhibits a moderate ratio of power words to specific nouns. High-fluff headings like [H2] Pushing the Boundaries of Science are countered by the inclusion of specific named experts such as Nick France, Seng Cheng, and Sophia Zilber. The body text provides concrete statistics on the ‘Living with Rare’ page, including the ‘1 in 2’ diagnosis ratio for children and ‘90%’ of rare diseases lacking approved treatments, which significantly anchors the marketing claims in reality.
When multiple URL variants exist, AI generates multiple embeddings of the same page. Run a Canonical Identity Stability Audit to see whether your site resolves into a single authoritative version.
Minor drift is detected between the high-level ‘Innovation’ promises on the homepage and the actual sub-page content. The [H1] Innovation page is structurally thin with only 722 characters and three generic H3 categories (Data Science, Diagnostics, Genomics) without providing the technical depth promised by the hero section’s ‘Pioneering new possibilities’ claim. However, the ‘Living in Rare’ sub-page successfully delivers on the mission-driven signal of the homepage.
Identify the current state and friction diagnosis of your specific business model. Generate your Executive SEO Strategy to quantify the financial or conversion cost of strategic misalignment.
The site avoids common trust theatre traps like unverified testimonials. While the review_count is 0, the proof_links_count is 1 on every major page, leading to a robust ‘References’ section on the ‘Living with Rare’ page that cites the Orphanet Journal of Rare Diseases and the EveryLife Foundation. The presence of Veeva IDs (e.g., Veeva ID: GL/ALL/0039) serves as a high-authority signal of regulatory compliance in the pharmaceutical industry.
The proof density is high for a corporate pharma site, particularly regarding disease awareness. The site provides 8 specific external references to validate its claims about the rare disease landscape. The ratio of vague assertions like ‘pioneering new possibilities’ is balanced by the ‘Rare Disease by the Numbers’ section which uses five distinct data points to ground the narrative.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
Cliché density is the primary driver of the score, with heavy reliance on industry-standard phrases like ‘transforming patient outcomes,’ ‘patient-centric,’ and ‘science-driven solutions.’ The value proposition—’where science meets compassion’—is a standard pharmaceutical cliche that could be swapped with competitors like Sanofi Genzyme or Takeda. The template structure (About Us, Media, Research and Development) follows the standard big-pharma blueprint exactly.
Authority is well-established through the AstraZeneca affiliation and named ‘R&D Leading Voices.’ A small gap exists as these experts are not currently supported by Person schema or direct sameAs links to their academic or professional portfolios in the metadata. The technical implementation is professional, with clean heading hierarchies and Organization schema that includes social media sameAs links.
There is a slight disconnect between the ‘relentless sense of urgency’ claimed on the homepage and the lack of real-time pipeline updates or clinical trial result summaries on the ‘Innovation’ page. Most performance claims are backed by broad industry statistics rather than specific internal ‘Alexion-only’ performance metrics. However, the dated articles (as recent as May 21, 2026) suggest a current and active content footprint.
Medical Devices, Pharma & Biotech BS: Alexion, AstraZeneca Rare Disease (alexion.com)
The content perfectly aligns with the Pharma & Biotech category, specifically focusing on the rare disease therapeutic area. Evidence includes the use of Veeva IDs (GL/ALL/0071), mentions of regulatory pathways, and clinical trial design terminology.
Your site's meaning is determined by its graph, not its menus. Review the Internal Linking Architecture Framework to see how AI interprets nodes, edges, and authority flow inside your domain.
“The score of 28 reflects a 'Low BS' profile. Points were primarily deducted for Industry Cliché Density (Step 4) and the thin Information Density on the Innovation sub-page (Step 1). The site's adherence to pharma regulatory standards (Veeva IDs) and strong external proof paths on the living-in-rare page prevented a higher score.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 26, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Alexion, AstraZeneca Rare Disease to view the most current version of their content and see directly what the company offers.